Navigation Links
Culprit behind unchecked angiogenesis identified
Date:3/29/2012

This press release is available in German.

Angiogenesis, the growth of new blood vessels, is a complex process during which different signalling proteins interact with each other in a highly coordinated fashion. The growth factor VEGF and the Notch signalling pathway both play important roles in this process. VEGF promotes vessel growth by binding to its receptor, VEGFR2, while the Notch signalling pathway acts like a switch capable of suppressing angiogenesis. Until recently, scientists had assumed that Notch cancels the effects of VEGF through the downregulation of VEGFR2. Now, researchers at the Max Planck Institute for Molecular Biomedicine and the Westphalian Wilhelms-University in Mnster, Germany, were able to demonstrate that defective Notch signalling enables strong and deregulated vessel growth even when VEGF or VEGFR2 are inhibited. In this case, a different VEGF family receptor, VEGFR3, is strongly upregulated, promoting angiogenesis. "This finding might help explain drug resistance issues in certain types of cancer therapy and could become the basis for novel treatment strategies," suggests Ralf Adams, MPI's Executive Director and Chair of the Department of Tissue Biology and Morphogenesis.

An extensively branched network of blood vessels provides every organ of the body with nutrients and removes harmful metabolic waste products from tissues. Growth of this vascular system is essential for development and wound healing processes. Uncontrolled angiogenesis contributes to diseases like hemangiomas, the sponge-like overgrowth of blood vessels in the skin, or retinopathies impairing the eyesight of diabetic and elderly individuals. In cancer therapy, inhibition of angiogenesis is used to starve tumours and prevent the metastatic spread of cancer cells via the circulation. At present, this is most frequently done by targeting VEGF or its receptor VEGFR2. When their oxygen supply becomes inadequate, tissues begin to release VEGF, which binds to VEGFR2, activating the receptor and thereby triggering vessel growth. Thus, the formation of new blood vessels can be blocked by inhibiting VEGF or VEGFR2. Unfortunately, existing treatments are inadequate and, for reasons that are not yet known, some patients respond poorly or not at all to VEGF/VEGFR2 inhibition.

Now, Rui Benedito, a postdoctoral research fellow in Adams' Department, has demonstrated that inhibition of the Notch pathway in blood vessels of the mouse eye permits strong and deregulated vessel growth even when VEGF or VEGFR2 are inhibited. "It turns out that another VEGF family receptor, VEGFR3, takes over, promoting the formation of new blood vessels," explains Benedito. VEGFR3 is strongly upregulated in blood vessels in the absence of Notch and is active even without growth signals from the surrounding tissues.

"What we need to do now is confirm whether VEGFR3 and other Notch-regulated signals are in fact capable of promoting VEGF-independent vessel growth in eye disease or cancer not only in mice but also in humans," explains Adams. "It might become possible to predict whether patients, depending on their vascular Notch activation status, are going to respond to VEGF or VEGFR2 inhibition. This would allow physicians to choose alternative therapies if necessary. Here, too, collaboration between MPI, the medical faculty, and the University of Mnster is essential: "Our work is strongly benefitting from the excellent support provided by the University."


'/>"/>
Contact: Ralf H. Adams
ralf.adams@mpi-muenster.mpg.de
49-251-703-65400
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. Blue light culprit in red tide blooms
2. Rainfall suspected culprit in leaf disease transmission
3. Air pollution a culprit in worsening drought and flooding
4. Culprits and cures for obesity may reside in our gut
5. Brown tide culprit sequenced: Genome of the first of algal bloom species
6. Culprit found for increased stroke injury with diabetes
7. UT Southwestern researchers uncover culprits in life-threatening clotting disorder
8. Ultraviolet radiation not culprit killing amphibians, research shows
9. Nervous culprit found for Tassie devil facial tumor disease
10. Apple or pear shape is not main culprit to heart woes -- its liver fat
11. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Culprit behind unchecked angiogenesis identified
(Date:8/21/2019)... ... 21, 2019 , ... AbSci, a revolutionary synthetic biology company ... of complex protein therapeutics, today announced the appointment of Fred Larimore, PhD, to ... Larimore brings more than 30 years of experience in biopharmaceutical manufacturing and process ...
(Date:8/15/2019)... ... 2019 , ... Deep Science Ventures (DSV), a new paradigm for ... unit dedicated to building 100 companies over the next 10 years to address the ... , Deep Science Ventures was founded to create a better method for launching science ...
(Date:8/14/2019)... MARTINSRIED, Germany (PRWEB) , ... August 14, 2019 ... ... screening and characterization, announced today that they have opened a Customer Experience Center ... fueled the need for the new office. , The Munich CEC will be ...
Breaking Biology News(10 mins):
(Date:6/12/2019)... , ... June 12, 2019 , ... ... helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging ... has been signed. The agreement will grant exclusive rights for Zillion to represent ...
(Date:6/11/2019)... CITY, Calif. (PRWEB) , ... June 10, 2019 ... ... (IOPP) today announced IOPP will add 80 of its scientific journals to DeepDyve’s ... of physics-related content to DeepDyve’s continually expanding library of more than 20 million ...
(Date:6/11/2019)... DURHAM, N.C. (PRWEB) , ... June 11, 2019 ... ... how extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to ... and cloning ability. In a test on mice, MSC-EVs also increased the cells’ ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... proprietary interest to our methodology, processes, and diagnostic techniques. The patent applications ... Somnology’s IP rights including our proprietary sleep scoring methodology. The approval and ...
Breaking Biology Technology: